How to manage treatment-resistant chronic migraine effectively?

Question

Hello doctor,

I have been suffering from severe, debilitating migraines for years, occurring 10 to 12 times per month and completely disabling me for six to 12 hours each time. These episodes force me to miss work and family obligations regularly. The pain is intense and throbbing, usually starting on the right side of my head and sometimes spreading. It is often accompanied by severe nausea with vomiting, extreme sensitivity to light and sound, and visual disturbances such as zigzag lines before the headache begins.

I have tried multiple preventive medications, including Propranolol, Amitriptyline, and Topiramate, with minimal success. Even my rescue medications, like triptans, have become less effective. I have identified several triggers, including stress, hormonal fluctuations around my menstrual cycle, certain foods such as chocolate and aged cheese, lack of sleep, bright lights, and weather changes with barometric pressure shifts.

The frequency and severity of my migraines are worsening, significantly affecting my job performance, relationships, and mental health. What newer treatment options are available, such as CGRP monoclonal antibodies, Botox injections, or nerve blocks, that might be more effective for someone with chronic, treatment-resistant migraines like mine?

Kindly advise.

Answer 1

Hello,

Welcome to icliniq.com.

I understand your concern.

The symptoms are consistent with chronic migraine, which is defined as headaches occurring on more than 15 days per month, with at least eight days having migraine features. Since standard preventive medicines have not been effective, several newer and evidence-based options are available:

These are given as monthly or quarterly injections and specifically block the calcitonin gene-related peptide (CGRP) pathway, which plays a key role in migraine. Medicines in this group include Erenumab, Fremanezumab, Galcanezumab, and Eptinezumab. They can reduce the frequency and intensity of migraines by approximately 50 to 70 percent in many patients who have not responded to older preventive therapies. Benefits may appear within one to two months. They are generally well tolerated. Mild constipation or injection-site reactions are the most commonly reported side effects. Routine blood tests are not usually required, but follow-up every three to six months is recommended to monitor progress.
OnabotulinumtoxinA is approved for chronic migraine (more than 15 headache days per month). It is injected into specific head and neck muscles every 12 weeks, usually across 31 injection sites. It works by reducing pain signal transmission and muscle tension. The effect is often noticeable after the second treatment session. Side effects are generally mild and may include temporary neck soreness, mild weakness, or a feeling of heaviness.
Occipital or supraorbital nerve blocks using a local anesthetic such as lidocaine, and sometimes a corticosteroid such as triamcinolone, can provide temporary relief lasting from weeks to months. These procedures may help interrupt a severe migraine cycle or enhance the effect of preventive therapy.
Neuromodulation devices, such as external vagus nerve stimulators or trigeminal nerve stimulators, may be beneficial, particularly for individuals who prefer non-pharmacological treatment options. These devices aim to reduce migraine frequency and severity by modulating pain pathways.
Maintaining regular sleep patterns, consistent meals, and adequate hydration is important. Stress management techniques such as yoga, biofeedback, or cognitive behavioral therapy (CBT) can also be helpful. For menstrual migraine, short-term preventive treatment with a triptan such as sumatriptan or frovatriptan around the menstrual period may reduce attack frequency.

A headache diary should be maintained. Tools such as the Migraine Disability Assessment (MIDAS) and the Headache Impact Test (HIT-6) can be used every three months to assess response to treatment. It is also important to evaluate for medication overuse headache, especially if triptans or analgesics are being used frequently.

In cases where oral preventive medicines have failed, starting either a Calcitonin Gene-Related Peptide (CGRP) monoclonal antibody or onabotulinumtoxinA injections is considered an appropriate next step. In selected cases, both therapies may be used together under specialist supervision for improved results.

I hope this helps you.

Thank you.